Samuel K. So

This paper develops a niclosamide sulfate prodrug, SSL-0024, which improves solubility and bioavailability, showing strong anti-tumor effects against hepatocellular carcinoma through multiple pathway inhibition.

This study develops a niclosamide prodrug (NIC-PS) with improved bioavailability and shows it targets VASN-TGFβ signaling to reduce HCC tumor volume and enhance therapeutic responses.

The paper analyzes 5-hydroxymethylcytosine in cell-free DNA to predict tumor types and stages with high accuracy.